Related Experiment Video

Updated: Feb 23, 2026

Differentiated Mouse Adipocytes in Primary Culture: A Model of Insulin Resistance
09:48

Differentiated Mouse Adipocytes in Primary Culture: A Model of Insulin Resistance

Published on: February 17, 2023

3.6K

Modulation of both Insulin Resistance and Cancer Growth by Inositol

Mariano Bizzarri1, Simona Dinicola2,3, Alessandra Cucina3,4

  • 1Department of Experimental Medicine, Faculty of Medicine and Dentistry, Sapienza University of Rome, Rome. Italy.

Current Pharmaceutical Design
|September 7, 2017
PubMed

Insights

Inositol, a natural compound, shows promise in treating both insulin resistance and cancer by modulating key biochemical pathways. Further clinical trials are needed to confirm its therapeutic potential in managing these conditions.

Area of Science:

  • Biochemistry
  • Metabolic Diseases
  • Oncology

Background:

  • Insulin resistance is implicated in type 2 diabetes and cancer development.
  • Inositol and its derivatives exhibit both anti-diabetic and anti-cancer effects.
  • Dysregulated inositol metabolism is linked to insulin resistance.

Purpose of the Study:

  • To explore the dual role of inositol in addressing insulin resistance and cancer.
  • To elucidate the biochemical mechanisms underlying inositol's therapeutic actions.
  • To evaluate the potential of inositol as a therapeutic agent for co-occurring metabolic and oncological conditions.

Main Methods:

  • Review of biochemical pathways involved in insulin signaling and carcinogenesis.
  • Analysis of inositol's modulation of key cellular processes (e.g., antioxidant defenses, glucose metabolism).
  • Examination of inositol's impact on specific molecular targets (PI3K/Akt, PDH, AMPK-related pathways).

Main Results:

  • Inositol acts as an insulin mimetic, counteracting hyperglycemia and hyperinsulinemia.
  • Inositol modulates critical pathways shared by insulin resistance and cancer.
  • In vivo studies indicate inositol's efficacy in improving glucose homeostasis and inhibiting cancer growth.

Conclusions:

  • Inositol demonstrates potential as a dual-acting therapeutic agent for insulin resistance and cancer.
  • Shared biochemical pathways provide a mechanistic basis for inositol's combined effects.
  • Randomized clinical trials are warranted to validate inositol's clinical utility.
Keywords:
PI3K/Aktaerobic glycolysisanti-cancerinositol-glycaninsulin resistancemyo-inositol

More Related Videos

Studying the Hypothalamic Insulin Signal to Peripheral Glucose Intolerance with a Continuous Drug Infusion System into the Mouse Brain08:32

Studying the Hypothalamic Insulin Signal to Peripheral Glucose Intolerance with a Continuous Drug Infusion System into the Mouse Brain

Published on: January 4, 2018

10.9K
Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment11:13

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

2.4K

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.9K
Psychoneuroimmunology: Diabetes and Cancer01:19

Psychoneuroimmunology: Diabetes and Cancer

Chronic stress has been linked to both the onset and progression of serious health conditions, including Type 2 diabetes and cancer. Type 2 diabetes, a widespread chronic illness, is closely associated with obesity and insulin resistance, both of which often worsen under stress. Studies indicate that men experiencing high levels of chronic stress face a 45% higher risk of developing diabetes compared to those with minimal stress. Stress triggers physiological responses that elevate blood...
542
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.1K
Insulin: The Receptor and Signaling Pathways01:28

Insulin: The Receptor and Signaling Pathways

Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but...
3.8K
Cancer Prevention02:59

Cancer Prevention

Several factors can increase the risk of cancer in an individual. About 50% of cancer cases can be prevented by adopting a healthy lifestyle, regular exercise, eating healthy, and following a modest cancer prevention diet. Epidemiological studies have consistently shown that populations with vegetable and fruit-rich diets have reduced the incidence of cancer. On the other hand, populations who have a diet rich in animal fat, red meat, junk food, or high calories are predisposed to cancer.
Some...
8.2K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
5.8K